Some studies have indicated that bone marrow stromal cell-derived cytokine Interleukin-6 (IL-6) can upregulate MCL-1 and BCL-XL expression in myeloma cells, thus providing a possible mechanism of resistance to venetoclax (55). The gene discussed is BCL2L1; the disease is plasma cell myeloma.